369 related articles for article (PubMed ID: 16321607)
21. alpha,alpha'-trehalose 6,6'-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying.
Christensen D; Kirby D; Foged C; Agger EM; Andersen P; Perrie Y; Nielsen HM
Biochim Biophys Acta; 2008 May; 1778(5):1365-73. PubMed ID: 18261458
[TBL] [Abstract][Full Text] [Related]
22. The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling.
Desel C; Werninghaus K; Ritter M; Jozefowski K; Wenzel J; Russkamp N; Schleicher U; Christensen D; Wirtz S; Kirschning C; Agger EM; Prazeres da Costa C; Lang R
PLoS One; 2013; 8(1):e53531. PubMed ID: 23308247
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N',N'-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses.
Henriksen-Lacey M; Christensen D; Bramwell VW; Lindenstrøm T; Agger EM; Andersen P; Perrie Y
Mol Pharm; 2011 Feb; 8(1):153-61. PubMed ID: 21117621
[TBL] [Abstract][Full Text] [Related]
24. Increased potential of a cationic liposome-based delivery system: enhancing stability and sustained immunological activity in pre-clinical development.
Mohammed AR; Bramwell VW; Kirby DJ; McNeil SE; Perrie Y
Eur J Pharm Biopharm; 2010 Nov; 76(3):404-12. PubMed ID: 20884349
[TBL] [Abstract][Full Text] [Related]
25. Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response.
Kaur R; Bramwell VW; Kirby DJ; Perrie Y
J Control Release; 2012 Dec; 164(3):331-7. PubMed ID: 22800572
[TBL] [Abstract][Full Text] [Related]
26. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
[TBL] [Abstract][Full Text] [Related]
27. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio.
Hamborg M; Rose F; Jorgensen L; Bjorklund K; Pedersen HB; Christensen D; Foged C
Biochim Biophys Acta; 2014 Aug; 1838(8):2001-10. PubMed ID: 24769435
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
[TBL] [Abstract][Full Text] [Related]
29. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
Yu H; Jiang X; Shen C; Karunakaran KP; Jiang J; Rosin NL; Brunham RC
Infect Immun; 2010 May; 78(5):2272-82. PubMed ID: 20231405
[TBL] [Abstract][Full Text] [Related]
30. Protein antigen adsorption to the DDA/TDB liposomal adjuvant: effect on protein structure, stability, and liposome physicochemical characteristics.
Hamborg M; Jorgensen L; Bojsen AR; Christensen D; Foged C
Pharm Res; 2013 Jan; 30(1):140-55. PubMed ID: 22956169
[TBL] [Abstract][Full Text] [Related]
31. Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses.
Milicic A; Kaur R; Reyes-Sandoval A; Tang CK; Honeycutt J; Perrie Y; Hill AV
PLoS One; 2012; 7(3):e34255. PubMed ID: 22470545
[TBL] [Abstract][Full Text] [Related]
32. Toll like-receptor agonist Pam
Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
[TBL] [Abstract][Full Text] [Related]
33. Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo.
Nordly P; Agger EM; Andersen P; Nielsen HM; Foged C
Pharm Res; 2011 Mar; 28(3):553-62. PubMed ID: 21042837
[TBL] [Abstract][Full Text] [Related]
34. Immunocorrelates of CAF family adjuvants.
Pedersen GK; Andersen P; Christensen D
Semin Immunol; 2018 Oct; 39():4-13. PubMed ID: 30396811
[TBL] [Abstract][Full Text] [Related]
35. Nano-Self-Assemblies Based on Synthetic Analogues of Mycobacterial Monomycoloyl Glycerol and DDA: Supramolecular Structure and Adjuvant Efficacy.
Martin-Bertelsen B; Korsholm KS; Roces CB; Nielsen MH; Christensen D; Franzyk H; Yaghmur A; Foged C
Mol Pharm; 2016 Aug; 13(8):2771-81. PubMed ID: 27377146
[TBL] [Abstract][Full Text] [Related]
36. APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice.
Soleimanpour S; Farsiani H; Mosavat A; Ghazvini K; Eydgahi MR; Sankian M; Sadeghian H; Meshkat Z; Rezaee SA
Appl Microbiol Biotechnol; 2015 Dec; 99(24):10467-80. PubMed ID: 26373723
[TBL] [Abstract][Full Text] [Related]
37. Scale-Independent Microfluidic Production of Cationic Liposomal Adjuvants and Development of Enhanced Lymphatic Targeting Strategies.
Roces CB; Khadke S; Christensen D; Perrie Y
Mol Pharm; 2019 Oct; 16(10):4372-4386. PubMed ID: 31437396
[TBL] [Abstract][Full Text] [Related]
38. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
[TBL] [Abstract][Full Text] [Related]
39. Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against
Tian M; Zhou Z; Tan S; Fan X; Li L; Ullah N
Front Immunol; 2018; 9():310. PubMed ID: 29535714
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of Th1-Type Immune Responses to
Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]